Industry

Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

KEYNOTE-716 is the first Phase 3 trial with an anti-PD-1/L1 to significantly improve distant metastasis-free survival (DMFS) and recurrence-free survival (RFS) for these patients Based on KEYNOTE-716, KEYTRUDA received US FDA approval and a positive EU CHMP opinion for the adjuvant treatment of patients aged 12 and older with completely resected stage IIB and IIC … [Read more…]

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Daiichi Sankyo and AstraZeneca’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary endpoint of progression free survival in patients with HR positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy ENHERTU is the first HER2 … [Read more…]

Creatv Bio’s LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Results to be presented at ASCO 2022 Annual Meeting in Chicago, IL ROCKVILLE, Md.–(BUSINESS WIRE)–Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of metastatic breast cancer (mBC) to new lines of therapy following a single cycle of therapy … [Read more…]

AHF Swiftly Brings Aid to Recife, Brazil

In the northeast state of Pernambuco, over 100 people have died due to torrential rains and flooding AHF Brazil, which provides HIV/AIDS care in 25 clinics in the country—including 3 clinics in Pernambuco and 5 in Recife—is delivering humanitarian aid to help over 600 individuals and families SÃO PAULO–(BUSINESS WIRE)–Following torrential rains and flooding that … [Read more…]

Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma

— In Three-Year Follow-up in Relapsed/Refractory Mantle Cell Lymphoma, Tecartus Induced High Rates of Durable Response (ORR 91%, 68% CR) and a Median Overall Survival of 46.6 Months — — In Two-Year Follow-up in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Tecartus Induced High Rates of Durable Response (CR+CRi 73.1%) and a Median Overall Survival … [Read more…]

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – 83% Reported Grade 3 Adverse Events of Special … [Read more…]

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

– 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – Promising Preliminary Efficacy and Safety Data from the Phase 1b/2 study of CG0070 in Combination with OPDIVO® … [Read more…]

Nucleai to Publish Pathology-based Data at ASCO 2022 for Phase 2 Research of the Most Common Type of Non-Hodgkin’s Lymphoma

CHICAGO–(BUSINESS WIRE)–#AIpowered–Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, today announced that it will share new data at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in an online publication on an exploratory analysis of a phase … [Read more…]

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

New preclinical data presented today at the American Diabetes Association’s annual conference suggests that the company’s superabsorbent hydrogel causes changes to the microbiota leading to weight loss and improvements in glucose tolerance and insulin sensitivity BOSTON–(BUSINESS WIRE)–Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional … [Read more…]

Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments

Data demonstrate Research Use Only ImPrint test’s ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform … [Read more…]